199 related articles for article (PubMed ID: 36990971)
1. Oral phosphodiesterase type 5 inhibitors and male reproductive potential: an overview.
Mostafa T; Alghobary M; Hanafy NS; Abosief A
Sex Med Rev; 2023 Jun; 11(3):240-252. PubMed ID: 36990971
[TBL] [Abstract][Full Text] [Related]
2. Effect of phosphodiesterase-5 inhibitors (PDE5is) on the treatment of male infertility: A protocol for systematic review and meta-analysis.
Dong L; Zhang X; Yan X; Shen Y; Yu X; Li Y
Medicine (Baltimore); 2019 Dec; 98(50):e18317. PubMed ID: 31852117
[TBL] [Abstract][Full Text] [Related]
3. Update on the Safety of Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction.
Yafi FA; Sharlip ID; Becher EF
Sex Med Rev; 2018 Apr; 6(2):242-252. PubMed ID: 28923561
[TBL] [Abstract][Full Text] [Related]
4. Recreational Use of Oral PDE5 Inhibitors: The Other Side of Midnight.
Mostafa T; Alghobary MF
Sex Med Rev; 2022 Jul; 10(3):392-402. PubMed ID: 34903486
[TBL] [Abstract][Full Text] [Related]
5. PDE5 inhibitors and male reproduction: Is there a place for PDE5 inhibitors in infertility clinics or andrology laboratories?
Dimitriadis F; Kaltsas A; Zachariou A; Mamoulakis C; Tsiampali C; Giannakis I; Paschopoulos M; Papatsoris A; Loutradis D; Tsounapi P; Takenaka A; Sofikitis N
Int J Urol; 2022 Dec; 29(12):1405-1418. PubMed ID: 36194789
[TBL] [Abstract][Full Text] [Related]
6. Effect of Genetic Polymorphism on the Response to PDE5 Inhibitors in Patients With Erectile Dysfunction: A Systematic Review and a Critical Appraisal.
Mostafa T; Hassan A; Alghobary MF; Abdelrahman SH
Sex Med Rev; 2020 Oct; 8(4):573-585. PubMed ID: 32636154
[TBL] [Abstract][Full Text] [Related]
7. Effect of Phosphodiesterase-5 Inhibitors on the Treatment of Male Infertility: A Systematic Review and Meta-Analysis.
Dong L; Zhang X; Yan X; Shen Y; Li Y; Yu X
World J Mens Health; 2021 Oct; 39(4):776-796. PubMed ID: 33663030
[TBL] [Abstract][Full Text] [Related]
8. The safety of phosphodiesterase type 5 inhibitors for erectile dysfunction.
Ventimiglia E; Capogrosso P; Montorsi F; Salonia A
Expert Opin Drug Saf; 2016; 15(2):141-52. PubMed ID: 26752541
[TBL] [Abstract][Full Text] [Related]
9. Phosphodiesterases 5 Inhibitors and Erectile Dysfunction Recovery after Pelvic Surgery: Future Perspectives for New Drugs and New Formulations.
Lombardo R; Tema G; De Nunzio C
Curr Drug Targets; 2021; 22(1):31-37. PubMed ID: 32981502
[TBL] [Abstract][Full Text] [Related]
10. Phosphodiesterase Type-5 Inhibitor Prescription Patterns in the United States Among Men With Erectile Dysfunction: An Update.
Mulhall JP; Chopra I; Patel D; Hassan TA; Tang WY
J Sex Med; 2020 May; 17(5):941-948. PubMed ID: 32144034
[TBL] [Abstract][Full Text] [Related]
11. Phosphodiesterase 5 inhibitors for the treatment of erectile dysfunction: a trade-off network meta-analysis.
Chen L; Staubli SE; Schneider MP; Kessels AG; Ivic S; Bachmann LM; Kessler TM
Eur Urol; 2015 Oct; 68(4):674-80. PubMed ID: 25817916
[TBL] [Abstract][Full Text] [Related]
12. Useful Implications of Low-dose Long-term Use of PDE-5 Inhibitors.
Mostafa T
Sex Med Rev; 2016 Jul; 4(3):270-284. PubMed ID: 27871960
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and satisfaction rates of oral PDE5is in the treatment of erectile dysfunction secondary to spinal cord injury: a review of literature.
Rizio N; Tran C; Sorenson M
J Spinal Cord Med; 2012 Jul; 35(4):219-28. PubMed ID: 22925748
[TBL] [Abstract][Full Text] [Related]
14. Daily vardenafil for 6 months has no detrimental effects on semen characteristics or reproductive hormones in men with normal baseline levels.
Jarvi K; Dula E; Drehobl M; Pryor J; Shapiro J; Seger M
J Urol; 2008 Mar; 179(3):1060-5. PubMed ID: 18206950
[TBL] [Abstract][Full Text] [Related]
15. Comparative efficacy and safety of phosphodiesterase type 5 inhibitors for erectile dysfunction in diabetic men: a Bayesian network meta-analysis of randomized controlled trials.
Liao X; Qiu S; Bao Y; Wang W; Yang L; Wei Q
World J Urol; 2019 Jun; 37(6):1061-1074. PubMed ID: 30523399
[TBL] [Abstract][Full Text] [Related]
16. Sildenafil's impact on male infertility: what has changed in 20 years?
Scherzer ND; Le TV; Hellstrom WJG
Int J Impot Res; 2019 Mar; 31(2):71-73. PubMed ID: 30837720
[TBL] [Abstract][Full Text] [Related]
17. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis.
Yuan J; Zhang R; Yang Z; Lee J; Liu Y; Tian J; Qin X; Ren Z; Ding H; Chen Q; Mao C; Tang J
Eur Urol; 2013 May; 63(5):902-12. PubMed ID: 23395275
[TBL] [Abstract][Full Text] [Related]
18. Effect of phosphodiesterase type 5 inhibitors on sperm motility and acrosome reaction: An
Song SH; Shin DH; Her YS; Oh MH; Baek JW; Sung S; Eum JH; Heo Y; Kim DS
Investig Clin Urol; 2021 May; 62(3):354-360. PubMed ID: 33943054
[TBL] [Abstract][Full Text] [Related]
19. Male fertility following spinal cord injury: an update.
Ibrahim E; Lynne CM; Brackett NL
Andrology; 2016 Jan; 4(1):13-26. PubMed ID: 26536656
[TBL] [Abstract][Full Text] [Related]
20. A comparison of the available phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction: a focus on avanafil.
Evans JD; Hill SR
Patient Prefer Adherence; 2015; 9():1159-64. PubMed ID: 26316720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
